Research programme: antibody-coupled T-cell receptor therapeutics - Unum Therapeutics/Seattle Genetics

Drug Profile

Research programme: antibody-coupled T-cell receptor therapeutics - Unum Therapeutics/Seattle Genetics

Alternative Names: ACTR 707; Antibody-coupled T cell receptor + anti-GPC3 antibody; Antibody-coupled T cell receptor + humanized non-fucosylated anti-BCMA antibody; SEA-BCMA

Latest Information Update: 27 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Unum Therapeutics
  • Class Antibodies; Antineoplastics; T lymphocyte cell therapies
  • Mechanism of Action B-cell maturation antigen modulators; CD200 antigen inhibitors; Cell replacements; Glypican modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 19 Jun 2017 US FDA approves IND application for ACTR 707 in B-cell lymphoma
  • 12 Jun 2017 Unum Therapeutics plans a phase I trial for B-cell lymphoma (In adults, In the elderly, Second-line therapy or greater, Combination therapy) (NCT03189836)
  • 31 May 2016 Preclinical trials in Cancer in USA (Parenteral) before May 2016 (Unum's pipeline, May 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top